Effect of probiotics on intestinal barrier function

Annals of the New York Academy of Sciences

Volumn 1165, Issue , 2009, Pages 183-189

  Mennigen, Rudolf ^a   Bruewer, Matthias ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Bacterial translocation; Epithelial barrier; Inflammatory bowel disease; Intestinal barrier; Probiotics; Tight junction

Indexed keywords

BALSALAZIDE; MESALAZINE; PROBIOTIC AGENT;

CELIAC DISEASE; CLINICAL TRIAL; CRITICAL ILLNESS; DIARRHEA; DRUG EFFECT; ENTERITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INFECTION; HEPATIC ENCEPHALOPATHY; HUMAN; ILEITIS; INTESTINE FUNCTION; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS PLANTARUM; REVIEW; SACCHAROMYCES BOULARDII; STREPTOCOCCUS THERMOPHILUS; ULCERATIVE COLITIS;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 67249106286     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04059.x     Document Type: Review

References (64)

1. Clayburgh, D.R., L. Shen & J.R. Turner. 2004. A porous defense: the leaky epithelial barrier in intestinal disease. Lab. Invest. 84: 282-291.
2. Laukoetter, M.G., P. Nava & A. Nusrat. 2008. Role of the intestinal barrier in inflammatory disease. World J. Gastroenterol. 14: 401-407.
3. Bjarnason, I., A. MacPherson & D. Hollander. 1995. Intestinal permeability: an overview. Gastroenterology 108: 1566-1581.
4. Fiocchi, C. 1998. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115: 182-205.
5. Podolsky, D.K. 2002. Inflammatory bowel disease. N. Engl. J. Med. 347: 417-429.
6. Sandle, G.I., N. Higgs, P. Crowe, et al. 1990. Cellular basis for defective electrolyte transport in inflamed human colon. Gastroenterology 99: 97-105.
7. Schmitz, H., C. Barmeyer, M. Fromm, et al. 1999. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology 116: 301-309.
8. Gassler, N., C. Rohr, A. Schneider, et al. 2001. Inflammatory bowel disease is associated with changes of enterocytic junctions. Am. J. Physiol. Gastrointest. Liver Physiol. 281: G216-G228.
9. Kucharzik, T., S.V. Walsh, J. Chen, et al. 2001. Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. Am. J. Pathol. 159: 2001-2009.
10. Zeissig, S., C. Bojarski, N. Buergel, et al. 2004. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut 53: 1295-1302.
11. Zeissig, S., N. Buergel, D. Guenzel, et al. 2007. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut 56: 61-72.
12. Fuller, R. 1989. Probiotics in man and animals. J. Appl. Bacteriol. 66: 365-378.
13. Malchow, H.A. 1997. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J. Clin. Gastroenterol. 25: 653-658.
14. Venturi, A., P. Gionchetti, F. Rizzello, et al. 1999. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment. Pharmacol. Ther. 13: 1103-1108.
15. Gionchetti, P., F. Rizzello, A. Venturi, et al. 2000. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119: 305-309.
16. Gionchetti, P., F. Rizzello, U. Helwig, et al. 2003. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124: 1202-1209.
17. Mimura, T., F. Rizzello, U. Helwig, et al. 2004. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53: 108-114.
18. Gionchetti, P., F. Rizzello, C. Morselli, et al. 2007. High-dose probiotics for the treatment of active pouchitis. Dis. Colon Rectum 50: 2075-2082.
19. Resta-Lenert, S. & K.E. Barrett. 2003. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 52: 988-997.
20. Bruewer, M., A. Luegering, T. Kucharzik, et al. 2003. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J. Immunol. 171: 6164-6172.
21. Montalto, M., N. Maggiano, R. Ricci, et al. 2004. Lactobacillus acidophilus protects tight junctions from aspirin damage in HT-29 cells. Digestion 69: 225-228.
22. Bruewer, M., M. Utech, A.I. Ivanov, et al. 2005. Interferon-gamma induces internalization of epithelial tight junction proteins via a macropinocytosis-like process. FASEB J. 19: 923-933.
23. Parassol, N., M. Freitas, K. Thoreux, et al. 2005. Lactobacillus casei DN-114 001 inhibits the increase in paracellular permeability of enteropathogenic Es-cherichia coli-infected T84 cells. Res. Microbiol. 156: 256-262.
24. Zyrek, A.A., C. Cichon, S. Helms, et al. 2007. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol. 9: 804-816.
25. Yan, F. & D.B. Polk. 2002. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J. Biol. Chem. 277: 50959-50965.
26. Caballero-Franco, C., K. Keller, C. De Simone, et al. 2007. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G315-G322.
27. Bernet, M.F., D. Brassart, J.R. Neeser, et al. 1994. Lactobacillus acidophilus LA1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 35: 483-489.
28. Schlee, M., J. Harder, B. Köten, et al. 2008. Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. Clin. Exp. Immunol. 151: 528-535.
29. Madsen, K., A. Cornish, P. Soper, et al. 2001. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121: 580-591.
30. Qin, H.L., T.Y. Shen, Z.G. Gao, et al. 2005. Effect of lactobacillus on the gut microflora and barrier function of the rats with abdominal infection. World J. Gastroenterol. 11: 2591-2596.
31. Ewaschuk, J., R. Endersby, D. Thiel, et al. 2007. Prbiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis. Hepatology 46: 841-850.
32. Zareie, M., K. Johnson-Henry, J. Jury, et al. 2006. Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. Gut 55: 1553-1560.
33. Eutamene, H., F. Lamine, C. Chabo, et al. 2007. Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats. J. Nutr. 137: 1901-1907.
34. Seehofer, D, N. Rayes, R.A. Schiller, et al. 2004. Probiotics partly reverse increased bacterial translocation after simultaneous liver resection and colonic anastomosis in rats. J. Surg. Res. 117: 262-271.
35. Osman, N., D. Adawi, S. Ahrne, et al. 2004. Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium. Dig. Dis. Sci. 49: 320-327.
36. van Minnen, L.P., H.M. Timmermann, F. Lutgendorff, et al. 2007. Modification of intestinal flora with multispecies probiotics reduces bacterial translocation and improves clinical course in a rat model of acute pancreatitis. Surgery 141: 470-480.
37. Cario, E., G. Gerken & D.K. Podolsky. 2007. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 132: 1359-1374.
38. Poritz, L.S., K.I. Garver, C. Green, et al. 2007. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. J. Surg . Res. 140: 12-19.
39. Ukena, S.N., A. Singh, U. Dringenberg, et al. 2007. Probiotic Escherichia coliNissle 1917 inhibits leaky gut by enhancing mucosal integrity. PloS ONE 2: e1308.
40. Ramakers, J.D., M.I. Verstege, G. Thuijls, et al. 2007. The PPARgamma agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis. J. Clin. Immunol. 27: 275-283.
41. Chapman, T.M., G.L. Plosker & D.P. Figgitt. 2006. VSL#3 probiotic mixture. A review of its use in chronic inflammatory bowel diseases. Drugs 66: 1371-1387.
42. Grabig, A., D. Paclik, C. Guzy, et al. 2006. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect. Immun. 74: 4075-4082.
43. Bai, A.P. & Q. Ouyang. 2006. Probiotics and inflammatory bowel diseases. Postgrad. Med. J. 82: 376-382.
44. Rachmilewitz, D., K. Katakura, F. Karmeli, et al. 2004. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126: 520-528.
45. Gupta, P., H. Andrew, B.S. Kirschner, et al. 2000. Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J. Pediatr. Gastroenterol. Nutr. 31: 453-457.
46. Garcia Vilela, E., M. de Lourdes de Abreu Ferrari, H. Oswaldo da Gama Torres, et al. 2008. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand. J. Gastroenterol. 43: 842-848.
47. Guslandi, M., G. Mezzi, M. Sorghi, et al. 2000. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig. Dis. Sci. 45: 1462-1464.
48. Prantera, C., M.L. Scribano, G. Falasco, et al. 2002. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 51: 405-409.
49. Schultz, M., A. Timmer, H.H. Herfarth, et al. 2004. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol. 4: 5.
50. Bibiloni, R., R.N. Fedorak, G.W. Tannock, et al. 2005. VSL#3 probiotic mixture induces remission in patients with active ulcerative colitis. Am. J. Gastroenterol. 100: 1539-1546.
51. Tursi, A., G. Brandimarte, G.M. Giorgetti, et al. 2004. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med. Sci. Monit. 20: PI126-131.
52. Liu, Q., Z.P. Duan, D.K. Ha, et al. 2004. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 39: 1441-1449.
53. Zeng, J., Y.Q. Li, X.L. Zuo, et al. 2008. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 28: 994-1002.
54. Sentongo, T.A., V. Cohran, S. Korff, et al. 2008. Intestinal permeability and effects of Lactobacillus rhamnosus therapy in children with short bowel syndrome. J. Pediatr. Gastroenterol. Nutr. 46: 41-47.
55. Rayes, N., D. Seehofer, T. Theruvath, et al. 2005. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation - a randomized, double-blind trial. Am. J. Transplant. 5: 125-130.
56. Rayes, N., D. Seehofer, T. Theruvath, et al. 2007. Effect of enteral nutrition and synbiotics on bacterial infection rates after pylorus-preserving pancre-atoduodenectomy. A randomized, double-blind trial. Ann. Surg. 246: 36-41.
57. Reddy, B.S., J. Macfie, M. Gatt, et al. 2007. Randomized clinical trial of effect of synbiotics, neomycin and mechanical bowel preparation on intestinal barrier function in patients undergoing colectomy. Br. J. Surg. 94: 546-554.
58. McNaught, C.E., N.P. Woodcock, J. MacFie, et al. 2002. A prospective randomised study of the probiotic Lactobacillus plantarum 299v on indices of gut barrier function in elective surgical patients. Gut 51: 827-831.
59. Jain, P.K., C.E. McNaught, A.D. Anderson, et al. 2004. Influence of synbiotic containing Lactobacillus acidophilus La5, Bifidobacterium lactis Bb12, Streptococcus thermophilus, Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: a randomised controlled trial. Clin. Nutr. 23: 467-475.
60. Olah, A., T. Belagyi, A. Issekutz, et al. 2002. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. Br. J. Surg. 89: 1103-1107.
61. Olah, A., T. Belagyi, L. Poto, et al. 2007. Synbiotic control of inflammation and infection in severe acute pancreatitis: a prospective, randomized, double blind study. Hepatogastroenterology 54: 590-594.
62. Honeycutt, T.C., M. El Khashab, R.M. Wardrop, et al. 2007. Probiotic administration and the incidence of nosocomial infection in pediatric intensive care: a randomized placebo-controlled trial. Pediatr. Crit. Care Med. 8: 452-458.
63. Besselink, M.G.H., H.C. van Santvoort, E. Buskens, et al. 2008. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371: 651-659.
64. Mennigen, R., K. Nolte, E.M. Rijcken, et al. 2009. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am. J. Physiol. Gastrointest. Liver Physiol. [Epub ahead of print].